B Cell Responses in COVID-19

B Cell Responses in COVID-19: Generation of SARS-CoV-2 Neutralizing Human Monoclonal Antibodies to Efficiently Contrast Wild-type and Emerging Variants.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06891170

Enrollment

Registered

2025-03-24

Start date

2021-07-07

Completion date

2025-03-31

Last updated

2025-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID 19

Brief summary

In this study, we will develop techniques to optimize the in vitro production of human monoclonal antibodies.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

* Age \>18 at time of signing informed consent form * Signed informed consent form

Exclusion criteria

* Ongoing drug abuse * Active or history of neoplastic malignancy * Active autoimmune disease ongoing treatment with immunosuppressive therapy * Ischemic heart disease * Evidence of positive HIV, HCV, HBV test * Diabetes * Failure to sign informed consent form

Design outcomes

Primary

Measure	Time frame
Optimization of the method to obtain human mAbs neutralizing COVID-19.	From enrollment to 24 weeks

Countries

Italy

Outcome results